Sectors
INBX
Inhibrx Biosciences Inc.
88.66
1 x 86.89
1 x 89.58
bid
ask
+
2.87
3.35%
1 @ 04:00 PM
88.00 -0.66 (0.74%)
| Ytd | 12.23% | |
| 1y | 315.46% |
80.42
day range
89.28
21.06
52 week range
141.84
| Open | 86.78 | Prev Close | 85.79 | Low | 80.42 | High | 89.28 | Mkt Cap | 1.30B |
| Vol | 407.63K | Avg Vol | 365.43K | EPS | -8.39 | P/E | -10.57 | Forward P/E | -14.76 |
| Beta | 3.43 | Short Ratio | 10.24 | Inst. Own | 82.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 92.75 | 200-d Avg | 84.03 | 1yr Est | 277.50 |
| Income Statement | |||
| Operating Expenses | 30.93M | ||
| Research and Development Expense | 25.22M | ||
| Selling, General and Administrative Expense | 5.71M | ||
| Operating Income | -30.93M | ||
| Interest Expense | 3.51M | ||
| Net Income | -33.44M | ||
| Net Income Common Stock | -33.44M | ||
| Net Income Common Stock (USD) | -33.44M | ||
| Consolidated Income | -33.44M | ||
| Earnings per Basic Share | -2.15 | ||
| Earnings per Basic Share (USD) | -2.15 | ||
| Earnings per Diluted Share | -2.15 | ||
| Earning Before Interest & Taxes (EBIT) | -29.93M | ||
| Earning Before Interest & Taxes (USD) | -29.93M | ||
| Weighted Average Shares | 15.59M | ||
| Weighted Average Shares Diluted | 15.59M | ||
| Balance Sheet | |||
| Cash and Equivalents | 161.66M | ||
| Cash and Equivalents (USD) | 161.66M | ||
| Trade and Non-Trade Receivables | 186.00K | ||
| Current Assets | 171.34M | ||
| Property, Plant & Equipment Net | 8.25M | ||
| Total Assets | 183.97M | ||
| Debt Current | 2.41M | ||
| Total Debt | 180.90M | ||
| Current Liabilities | 26.51M | ||
| Debt Non-Current | 178.49M | ||
| Total Liabilities | 205.00M | ||
| Accumulated Retained Earnings (Deficit) | -279.63M | ||
| Shareholders Equity | -21.03M | ||
| Shareholders Equity (USD) | -21.03M | ||
| Assets Non-Current | 12.63M | ||
| Total Debt (USD) | 180.90M | ||
| Liabilities Non-Current | 178.49M | ||
| Trade and Non-Trade Payables | 8.76M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.02M | ||
| Net Cash Flow from Financing | 75.46M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 37.44M | ||
| Issuance (Purchase) of Equity Shares | 471.00K | ||
| Issuance (Repayment) of Debt Securities | 74.99M | ||
| Net Cash Flow from Operations | -38.03M | ||
| Share Based Compensation | 2.65M | ||